- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05825404
Smart Lighting for Nursing Home Residents With Dementia
December 12, 2023 updated by: Ying-Ling Jao RN, PhD, FGSA, Penn State University
The Effect of Smart Ambient Bright Light for Nursing Home Residents With Alzheimer's Disease and Related Dementias
This proposed study seeks to develop a smart ambient bright light (SABL) intervention to provide auto-controlled, consistent indoor lighting that incorporates natural daylight.
This SABL includes tunable LED lights, photosensors, and controllers.
The SABL system has a pre-programmed 24-hour control schedule for illuminance settings to mimic the natural bright-dark cycle.
It will automatically adjust the lights to accommodate the daylight effect to minimize staff burden and maximize the LI effect.
The SABL will be installed in participants' bedrooms and designated areas in the dining rooms and activity rooms for four weeks.
Each participant will wear a personal light monitor to measure the lighting dosage each participant receives.
This study will address three aims: 1) pilot test the effect of SABL on reducing agitation in persons with ADRD, 2) evaluate the fidelity of the SABL delivery, and 3) evaluate the feasibility of implementing the SABL.
The study will be conducted in two NHs in Pennsylvania.
For aims 1 and 2, the investigators will use a crossover, cluster randomized control trial (RCT) and will enroll residents with ADRD and agitation.
For aim 3, the investigators will use a mixed methods design and will interview NH stakeholders to evaluate the acceptability, feasibility, and appropriateness of the intervention.
This is the first study that incorporates daylight in ambient light interventions and the first study that addresses the measurement, feasibility, and fidelity of lighting interventions.
Findings will establish evidence-based implementation strategies and the best design for SABL to reduce agitation for persons with ADRD in NHs.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Up to 90% of people with Alzheimer's disease and related dementias (ADRD) experience at least one behavioral and psychological symptom of dementia (BPSD).
Agitation is among the most common and challenging BPSD, especially in nursing home (NH) residents with ADRD.
Thus, identifying an effective, non-pharmacological intervention to reduce agitation and other BPSDs is critical.
Lighting is important for people with ADRD, especially those living in NHs, as they are not exposed to sufficient daylight.
Lighting interventions (LIs) work to regulate suprachiasmatic nuclei, maintain a stable circadian rhythm and reduce agitation.
LIs are not invasive and have minimal adverse effects, making them ideal interventions for persons with ADRD.
Evidence has reported that LIs show improvement in agitation and other BPSDs for persons with ADRD.
However, LIs have not been widely implemented in "real world" care settings.
Traditional methods using light boxes that required persons with ADRD to sit and keep their eyes oriented toward a bright light led to compliance and workload issues.
A more efficient approach to delivering LIs is necessary.
Interest has arisen in designing NHs with the capability of providing LIs via ambient LIs.
While a few studies have reported positive effects of ambient LIs on agitation, these studies were conducted in settings with window shades closed to minimize daylight.
To establish ambient lighting as a feasible and effective intervention, a few fundamental gaps need to be addressed: 1) a feasible implementation approach to ambient LIs, and 2) intervention fidelity (ensuring the lighting received by participants meets the targets).
This proposed study seeks to develop a smart ambient bright light (SABL) intervention to provide auto-controlled, consistent indoor lighting that incorporates natural daylight.
This SABL includes tunable LED lights, photosensors, and controllers.
The SABL system has a pre-programmed 24-hour control schedule for illuminance settings to mimic the natural bright-dark cycle.
It will automatically adjust the lights to accommodate the daylight effect to minimize staff burden and maximize the LI effect.
The SABL will be installed in participants' bedrooms and designated areas in the dining rooms and activity rooms for four weeks.
Each participant will wear a personal light monitor to measure the lighting dosage each participant receives.
This study will address three aims: 1) pilot test the effect of SABL on reducing agitation in persons with ADRD, 2) evaluate the fidelity of the SABL delivery, and 3) evaluate the feasibility of implementing the SABL.
The study will be conducted in two NHs in Pennsylvania.
For aims 1 and 2, the investigators will use a crossover, cluster randomized control trial (RCT) and will enroll residents with ADRD and agitation.
For aim 3, the investigators will use a mixed methods design and will interview NH stakeholders to evaluate the acceptability, feasibility, and appropriateness of the intervention.
This is the first study that incorporates daylight in ambient light interventions and the first study that addresses the measurement, feasibility, and fidelity of lighting interventions.
Findings will establish evidence-based implementation strategies and the best design for SABL to reduce agitation for persons with ADRD in NHs.
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ying-Ling Jao, PhD
- Phone Number: 814-865-5634
- Email: yuj15@psu.edu
Study Contact Backup
- Name: Julian Wang, PhD
- Email: Jqw5965@psu.edu
Study Locations
-
-
Pennsylvania
-
Belleville, Pennsylvania, United States, 17004
- Recruiting
- Valley View Retirement Community
-
Contact:
- Nicole Sarver
- Email: nsarver@vvrconline.org
-
DuBois, Pennsylvania, United States, 15801
- Active, not recruiting
- Christ the King Manor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age≥55
- English speaking
- Nursing home residency≥3 months
- Clinical Diagnosis of Alzheimer's Disease and related dementia
- Presence of agitation over the past week
Exclusion Criteria:
- Major sleep problems
- Major mental illness
- Severe vision impairment
- Severe acute or terminal illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Smart ambient bright light
The smart ambient bright light (SABL) intervention provides auto-controlled, consistent indoor lighting that incorporates natural daylight.
|
The Proposed Smart Ambient Bright Light (SABL) includes tunable LED lights, photosensors, and controllers.
The SABL will provide bright light targeted at 400 lux and CS=0.3 in participant bedrooms and designated areas such as the dining room and activity room during the day and provide dim light ≤40 lux and CS≤0.1 in participant bedrooms at night
|
Sham Comparator: Control
Usual light.
|
Usual light.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in light level: Lux at the facility level
Time Frame: Twice a week for 13 weeks
|
Light level (lux) at the facility level will be measured manually on-site.
|
Twice a week for 13 weeks
|
Change in light level: CS at the facility level
Time Frame: Twice a week for 13 weeks
|
Light level (CS) at the facility level will be measured manually on-site.
|
Twice a week for 13 weeks
|
Change in light level: Lux at the individual level
Time Frame: Weeks 1, 3, 5, 7, 9, 11, and 13
|
Light level (lux) at the individual level will be measured using a personal light monitor.
|
Weeks 1, 3, 5, 7, 9, 11, and 13
|
Change in light level: CS at the individual level
Time Frame: Weeks 1, 3, 5, 7, 9, 11, and 13
|
Light level (CS) at the individual level will be measured using a personal light monitor.
|
Weeks 1, 3, 5, 7, 9, 11, and 13
|
Change in agitation
Time Frame: Weeks 1, 3, 5, 7, 9, 11, and 13
|
Agitation will be measured using the Cohen Mansfield Agitation Inventory (CMAI) based on the primary care healthcare workers' (RN, LPN, or CNA) observations over the previous week.
The total score ranges from 29 to 203; a higher score indicates a higher agitation level.
|
Weeks 1, 3, 5, 7, 9, 11, and 13
|
Intervention acceptability
Time Frame: Week 13
|
The intervention acceptability of the lighting intervention will be measured based on nursing home stakeholders' perspectives using the Acceptability of Intervention Measure (AIM) and followed up by qualitative interviews.
The total score ranges from 12-60; a higher score indicates a higher level of acceptability.
|
Week 13
|
Intervention feasibility
Time Frame: Week 13
|
The intervention feasibility of the lighting intervention will be measured based on nursing home stakeholders' perspectives using the Feasibility of Intervention Measure (FIM) and followed up by qualitative interviews.
The total score ranges from 9-45; a higher score indicates a higher level of feasibility.
|
Week 13
|
Intervention appropriateness
Time Frame: Week 13
|
The intervention appropriateness of the lighting intervention will be measured based on nursing home stakeholders' perspectives using the Intervention Appropriateness Measure (IAM) and followed up by qualitative interviews.
The total score ranges from 10-50; a higher score indicates a higher level of appropriateness.
|
Week 13
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Behavioral and Psychological Symptoms of Dementia (BPSD)
Time Frame: Weeks 1, 3, 5, 7, 9, 11, and 13
|
12 BPSDs will be measured, including delusions, hallucinations, dysphoria, euphoria, anxiety, agitation/aggression, apathy, irritability, disinhibition, aberrant motor behaviors, sleep, and appetite.
BPSD will be measured using the Neuropsychiatry Inventory-Nursing Home version (NPI-NH).
Each behavioral symptom is rated on a 0-3 scale; a higher score indicates a more severe of symptom.
|
Weeks 1, 3, 5, 7, 9, 11, and 13
|
Affect
Time Frame: Weeks 1, 3, 5, 7, 9, 11, and 13
|
Six affective states will be measured: contentment, interest, pleasure, anxiety/fear, anger, and sadness, using the Philadelphia Geriatric Center Affect Rating Scale.
Each item is rated on a 5-point scale (1-5); a higher score indicates a higher level of affect.
|
Weeks 1, 3, 5, 7, 9, 11, and 13
|
Adverse effects.
Time Frame: Weeks 1, 3, 5, 7, 9, 11, and 13
|
Data on intervention-related adverse effects will be collected via inputs from certified nurse assistants (CNAs) using a checklist, which includes deteriorated BPSDs, skin rash, eye irritation, dizziness, nausea, or any other reactions.
Each item will be checked as yes or no.
|
Weeks 1, 3, 5, 7, 9, 11, and 13
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ying-Ling Jao, PhD, Penn State University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Figueiro MG, Plitnick B, Roohan C, Sahin L, Kalsher M, Rea MS. Effects of a Tailored Lighting Intervention on Sleep Quality, Rest-Activity, Mood, and Behavior in Older Adults With Alzheimer Disease and Related Dementias: A Randomized Clinical Trial. J Clin Sleep Med. 2019 Dec 15;15(12):1757-1767. doi: 10.5664/jcsm.8078. Epub 2019 Nov 8.
- Figueiro MG, Hunter CM, Higgins P, Hornick T, Jones GE, Plitnick B, Brons J, Rea MS. Tailored Lighting Intervention for Persons with Dementia and Caregivers Living at Home. Sleep Health. 2015 Dec 1;1(4):322-330. doi: 10.1016/j.sleh.2015.09.003.
- Jao YL, Wang J, Liao YJ, Parajuli J, Berish D, Boltz M, Van Haitsma K, Wang N, McNally L, Calkins M. Effect of Ambient Bright Light on Behavioral and Psychological Symptoms in People With Dementia: A Systematic Review. Innov Aging. 2022 Mar 24;6(3):igac018. doi: 10.1093/geroni/igac018. eCollection 2022.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 24, 2023
Primary Completion (Estimated)
February 15, 2024
Study Completion (Estimated)
February 15, 2024
Study Registration Dates
First Submitted
March 28, 2023
First Submitted That Met QC Criteria
April 21, 2023
First Posted (Actual)
April 24, 2023
Study Record Updates
Last Update Posted (Estimated)
December 18, 2023
Last Update Submitted That Met QC Criteria
December 12, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00020216
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease and Related Dementias
-
Rutgers, The State University of New JerseyNational Institute on Aging (NIA)Not yet recruitingAlzheimer's Disease and Related Dementias
-
Northwell HealthNational Institute of Nursing Research (NINR); Penn State UniversityCompletedAlzheimer's Disease and Related DementiasUnited States
-
University of IowaNational Institute on Aging (NIA)Completed
-
Northwell HealthNational Institute of Nursing Research (NINR); Penn State UniversityCompletedAlzheimer's Disease and Related DementiasUnited States
-
Harvard Pilgrim Health CareNational Institute on Aging (NIA); Tufts Health PlanActive, not recruitingAlzheimer's Disease and Related Dementias (ADRD)United States
-
Florida State UniversityNational Institute of Nursing Research (NINR)CompletedAlzheimer's Disease and Related DementiasUnited States
-
Arizona State UniversityRecruitingAlzheimer's Disease and Related Dementias Family CaregiversUnited States
-
Massachusetts General HospitalNational Institute on Aging (NIA); University of California, San FranciscoRecruitingQuality of Life | Caregiver Stress | Alzheimer's Disease and Related DementiasUnited States
-
University of South FloridaNational Institute on Aging (NIA)RecruitingAge-related Cognitive Decline | Alzheimer's Disease and Related DementiasUnited States
-
Rutgers, The State University of New JerseyNational Institute on Aging (NIA)RecruitingAlzheimer's Disease and Related DementiasUnited States
Clinical Trials on Smart Ambient Bright Light (SABL)
-
University of ArizonaU.S. Army Medical Research Acquisition ActivityCompletedConcussion, Mild | Sleep Problems | Post-Concussion SymptomsUnited States
-
China Medical University HospitalNot yet recruiting
-
Matthew Neal MDTerminatedPancreatic Neoplasms | Rectal NeoplasmsUnited States
-
University of ArizonaU.S. Army Medical Research Acquisition ActivityCompletedConcussion, Mild | Sleep Problems | Post-Concussion SymptomsUnited States
-
Yale UniversityCompletedCircadian Rhythm Sleep Disorder, UnspecifiedUnited States
-
University of BergenCompleted
-
Radford UniversityCommonwealth Care of Roanoke, Inc.; Virginia Center on Aging (ARDRAF)Completed
-
National Eye Institute (NEI)CompletedRetinopathy of PrematurityUnited States
-
University of WashingtonIcahn School of Medicine at Mount Sinai; University of North Texas Health Science...CompletedSleep | Traumatic Brain Injury | TBIUnited States
-
Northwestern UniversityRush UniversityCompletedPreDiabetes | Circadian DysregulationUnited States